MEDBOT-B (02252) shares climbed more than 7% in early Hong Kong trading, reaching HK$21.74 at the time of writing, with a turnover of HK$67.42 million.

The company recently issued a profit alert, forecasting a net profit of between 28 million yuan and 40 million yuan for the first half of the year, compared with a loss of 115 million yuan in the same period last year. This marks the company's first-ever half-yearly profit. Revenue is expected to surge by approximately 200% to 230%, calculated to be between 527 million yuan and 580 million yuan.

Revenue from the company's key product, the Toumai surgical robot, surged over 450% in overseas markets, while overall gross margin improved by more than 15 percentage points.

Haitong International believes that the ramp-up in Toumai sales is driving significant revenue growth, with a continued high growth rate in overseas markets. The broker noted a sharp rise in gross margin and a further optimisation of the ratio of expenses to revenue. The profit turnaround in the first half was attributed to the combined effect of rising revenue, improved gross margin, and better cost control. As installations at hospitals both domestically and abroad accelerate, the company's scale effect and operating leverage are expected to gradually emerge.